These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 512841)

  • 1. Pharmacokinetic modeling of heparin and its clinical implications.
    McAvoy TJ
    J Pharmacokinet Biopharm; 1979 Aug; 7(4):331-54. PubMed ID: 512841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of heparin. II. Studies of time dependence in rats.
    Bjornsson TD; Levy G
    J Pharmacol Exp Ther; 1979 Aug; 210(2):243-6. PubMed ID: 458631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heparin kinetics in venous thrombosis and pulmonary embolism.
    Hirsh J; van Aken WG; Gallus AS; Dollery CT; Cade JF; Yung WL
    Circulation; 1976 Apr; 53(4):691-5. PubMed ID: 1253392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of anticoagulant effects and safety of argatroban and heparin in healthy subjects.
    Swan SK; St Peter JV; Lambrecht LJ; Hursting MJ
    Pharmacotherapy; 2000 Jul; 20(7):756-70. PubMed ID: 10907966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of defibrotide in healthy volunteers.
    Noseda G; Fragiacomo C; Ferrari D
    Haemostasis; 1986; 16 Suppl 1():26-30. PubMed ID: 3754833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved methods for estimating initial heparin infusion rates.
    Chenella FC; Gill MA; Kern JW; Floyd RA; McGehee WG
    Am J Hosp Pharm; 1979 Jun; 36(6):782-4. PubMed ID: 463894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Covalent complexes between low molecular weight heparin fragments and antithrombin III - inhibition kinetics and turnover parameters.
    Hoylaerts M; Holmer E; de Mol M; Collen D
    Thromb Haemost; 1983 Apr; 49(2):109-15. PubMed ID: 6868006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Perivascular graft heparin delivery using biodegradable polymer wraps.
    Edelman ER; Nathan A; Katada M; Gates J; Karnovsky MJ
    Biomaterials; 2000 Nov; 21(22):2279-86. PubMed ID: 11026634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heparin half-life and sensitivity in normal subjects and in patients affected by deep vein thrombosis.
    Benchekroun S; Eychenne B; Mericq O; Colombani A; Douste-Blazy P; Barret A; Sie P; Boneu B
    Eur J Clin Invest; 1986 Dec; 16(6):536-9. PubMed ID: 3104055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Heparin dosage in long-term intravenous administration based on the example of vascular surgery patients].
    Braun V; Homann B; Sperling M
    Anaesthesist; 1986 May; 35(5):291-8. PubMed ID: 3740376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isoform composition of antithrombin in a covalent antithrombin-heparin complex.
    Chan AK; Berry LR; Paredes N; Parmar N
    Biochem Biophys Res Commun; 2003 Oct; 309(4):986-91. PubMed ID: 13679071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Context-sensitive half-time in multicompartment pharmacokinetic models for intravenous anesthetic drugs.
    Hughes MA; Glass PS; Jacobs JR
    Anesthesiology; 1992 Mar; 76(3):334-41. PubMed ID: 1539843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The kinetics of heparin.
    Estes JW
    Ann N Y Acad Sci; 1971 Jul; 179():187-204. PubMed ID: 5285374
    [No Abstract]   [Full Text] [Related]  

  • 14. Pharmacokinetics of vindesine given as an intravenous bolus and 24-hour infusion in humans.
    Ohnuma T; Norton L; Andrejczuk A; Holland JF
    Cancer Res; 1985 Jan; 45(1):464-9. PubMed ID: 3965152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic and pharmacodynamic properties of eptifabatide in healthy subjects receiving unfractionated heparin or the low-molecular-weight heparin enoxaparin.
    Gretler DD
    Clin Ther; 2003 Oct; 25(10):2564-74. PubMed ID: 14667957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heparin's roles in stabilizing, potentiating, and transporting LEDGF into the nucleus.
    Fatma N; Singh DP; Shinohara T; Chylack LT
    Invest Ophthalmol Vis Sci; 2000 Aug; 41(9):2648-57. PubMed ID: 10937578
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The heterogeneity of the anticoagulant response to heparin.
    Estes JW
    J Clin Pathol; 1972 Jan; 25(1):45-8. PubMed ID: 5015373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heparin elimination following continuous infusion during intra-aortic balloon counterpulsation.
    Jacob AS; Steingart RH; Schweger MJ
    Cathet Cardiovasc Diagn; 1985; 11(4):389-92. PubMed ID: 4042156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Technetium 99m labelled heparin: pharmacokinetics and tissue distribution in rats after vascular surgery.
    Colas-Linhart N; Berthelot JL; Ducret A; Petiet A; Bok B
    Biomed Pharmacother; 1987; 41(4):189-91. PubMed ID: 3620586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The fate of heparin in the body.
    Estes JW
    Curr Ther Res Clin Exp; 1975 Jul; 18(1 Pt1):45-57. PubMed ID: 808390
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.